Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Sell
25
AVIR Quote, Financials, Valuation and Earnings
Last price:
$3.46
Seasonality move
:
-23.12%
Day range:
$3.43 - $3.67
52-week range:
$2.46 - $4.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.84x
P/B ratio:
0.85x
Volume:
315.1K
Avg. volume:
365.2K
1-year change:
3.29%
Market cap:
$269.5M
Revenue:
--
EPS (TTM):
-$1.78
Analysts' Opinion
-
Consensus RatingAtea Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, Atea Pharmaceuticals, Inc. has an estimated upside of 73.91% from its current price of $3.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $3.45.
Fair Value
-
According to the consensus of 3 analysts, Atea Pharmaceuticals, Inc. has 73.91% upside to fair value with a price target of $6.00 per share.
AVIR vs. S&P 500
-
Over the past 5 trading days, Atea Pharmaceuticals, Inc. has underperformed the S&P 500 by -2.4% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Atea Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Atea Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Atea Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Atea Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Atea Pharmaceuticals, Inc. reported earnings per share of -$0.53.
Enterprise value:
-58.7M
EV / Invested capital:
--
Price / LTM sales:
0.84x
EV / EBIT:
--
EV / Revenue:
-0.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$416K
Return On Assets:
-34.51%
Net Income Margin (TTM):
--
Return On Equity:
-36.97%
Return On Invested Capital:
-36.83%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$416K | -$416K | -$416K | -$104K | -$104K | |
| Operating Income | -$157.5M | -$200.5M | -$165M | -$37.2M | -$45.6M | |
| EBITDA | -$157.1M | -$200.1M | -$164.6M | -$37.1M | -$45.5M | |
| Diluted EPS | -$1.57 | -$2.07 | -$1.78 | -$0.37 | -$0.53 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $842.9M | $681.9M | $603.3M | $486.9M | $336.1M | |
| Total Assets | $843.5M | $686.6M | $608.1M | $491M | $343M | |
| Current Liabilities | $262.1M | $15.6M | $18.9M | $25.2M | $20.2M | |
| Total Liabilities | $262.1M | $23.4M | $26.3M | $32.4M | $27.2M | |
| Total Equity | $581.5M | $663.2M | $581.7M | $458.5M | $315.8M | |
| Total Debt | $279K | $2.6M | $1.8M | $1M | $213K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$85.1M | -$126.9M | -$134.2M | -$23M | -$40.4M | |
| Cash From Investing | $46M | $87.2M | $138.8M | -$122M | $41.3M | |
| Cash From Financing | $257K | $267K | -$25.7M | $117K | -$11.3M | |
| Free Cash Flow | -$85.1M | -$126.9M | -$134.2M | -$23M | -$40.4M | |
AVIR
Sector
Market Cap
$269.5M
$28.1M
Price % of 52-Week High
85.82%
51.87%
Dividend Yield
0%
0%
Shareholder Yield
11.24%
-1.59%
1-Year Price Total Return
3.29%
-17.31%
Beta (5-Year)
0.079
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.51
200-day SMA
Buy
Level
$3.20
Bollinger Bands (100)
Buy
Level
2.99 - 3.43
Chaikin Money Flow
Sell
Level
-39.4M
20-day SMA
Buy
Level
$3.35
Relative Strength Index (RSI14)
Buy
Level
54.71
ADX Line
Buy
Level
27.5
Williams %R
Neutral
Level
-41.0256
50-day SMA
Buy
Level
$3.23
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Sell
Level
-161.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2583)
Buy
CA Score
(Annual)
Level (-0.0962)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (9.4327)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, AVIR has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The AVIR average analyst price target in the past 3 months is $6.00.
-
Where Will Atea Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Atea Pharmaceuticals, Inc. share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Atea Pharmaceuticals, Inc.?
Analysts are divided on their view about Atea Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Atea Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Atea Pharmaceuticals, Inc.'s Price Target?
The price target for Atea Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $6.00 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is AVIR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Atea Pharmaceuticals, Inc. is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AVIR?
You can purchase shares of Atea Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Atea Pharmaceuticals, Inc. shares.
-
What Is The Atea Pharmaceuticals, Inc. Share Price Today?
Atea Pharmaceuticals, Inc. was last trading at $3.46 per share. This represents the most recent stock quote for Atea Pharmaceuticals, Inc.. Yesterday, Atea Pharmaceuticals, Inc. closed at $3.45 per share.
-
How To Buy Atea Pharmaceuticals, Inc. Stock Online?
In order to purchase Atea Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get AVIR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AVIR
Sector
P/E ratio
--
24.20x
PEG ratio
--
-0.01x
P/B ratio
0.85x
1.84x
Price / LTM sales
0.84x
1.60x
Growth Metrics
AVIR
Sector
Revenue growth
--
4.51%
Earnings growth
-44.15%
10.7%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.53
-$0.19
Profitability
AVIR
Sector
Profitability FY 2024
-$416K
$3.5M
Return on invested capital
-36.83%
-32.3%
Return on assets
-34.51%
-28.57%
Return on equity
-36.97%
-38.09%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
11
Balance Sheet
AVIR
Sector
Total cash
$329.3M
$26M
Short term investments
$390M
$25.7M
Total assets
$464.7M
$76.4M
Long term debt
$213K
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
